...
首页> 外文期刊>American Journal of Pathology >Osteoclasts from Patients with Autosomal Dominant Osteopetrosis Type I Caused by a T253I Mutation in Low-Density Lipoprotein Receptor-Related Protein 5 Are Normal in Vitro, but Have Decreased Resorption Capacity in Vivo
【24h】

Osteoclasts from Patients with Autosomal Dominant Osteopetrosis Type I Caused by a T253I Mutation in Low-Density Lipoprotein Receptor-Related Protein 5 Are Normal in Vitro, but Have Decreased Resorption Capacity in Vivo

机译:低密度脂蛋白受体相关蛋白5的T253I突变引起常染色体显性I型骨质疏松症患者的破骨细胞在体外是正常的,但体内吸收能力降低

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Autosomal dominant osteopetrosis type I (ADOI) is presumably caused by gain-of-function mutations in the LRP5 gene. Patients with a T253I mutation in LRP5 have a high bone mass phenotype, characterized by increased mineralizing surface index but abnormally low numbers of small osteoclasts. To investigate the effect of the T253I mutation in LRP5 on osteoclasts, we isolated CD14+ monocytes from ADOI patients and assessed their ability to generate osteoclasts when treated with RANKL and M-CSF compared to that of age- and sex-matched control osteoclasts. We found normal osteoclastogenesis, expression of osteoclast markers, morphology, and localization of proteins involved in bone resorption, such as ClC-7 and cathepsin K. The ability to resorb bone was also normal. In vivo, we compared the bone resorption and bone formation response to T3 in ADOI patients and age- and sex-matched controls. We found attenuated resorptive response to T3 stimulation, despite a normal bone formation response, in alignment with the reduced number of osteoclasts in vivo. These data demonstrate that ADOI osteoclasts are normal with respect to all aspects investigated in vitro. We speculate that the mutations causing ADOI alter the osteoblastic phenotype toward a smaller potential for supporting osteoclastogenesis.
机译:常染色体显性I型骨质疏松症(ADOI)可能是LRP5基因中的功能获得性突变引起的 。 LRP5中具有T253I突变的患者 具有高骨量表型, 的特征是矿化表面指数增加,但小破骨细胞数量异常 。为了研究LRP5中T253I突变对破骨细胞的影响,我们从ADOI患者中分离了CD14 + 单核细胞,并评估了它们在治疗后产生 破骨细胞的能力。与年龄和性别匹配的对照破骨细胞的 进行比较。我们发现正常的 破骨细胞发生,破骨细胞标志物的表达,形态, 以及与骨吸收有关的蛋白质的定位,例如 ,例如ClC-7和组织蛋白酶K。 。吸收骨骼的能力也是 。在体内,我们比较了ADOI患者和年龄和性别匹配的对照对T 3 的骨吸收和骨形成反应 尽管 骨骼形成正常,但对T 3 刺激的吸收反应却减弱,这与体内破骨细胞数量减少有关。这些数据表明,对于体外研究的所有方面,ADOI 破骨细胞都是正常的。我们推测引起ADOI的突变会改变成骨细胞表型向支持 破骨细胞生成的潜力。

著录项

  • 来源
    《American Journal of Pathology》 |2005年第5期|1341-1348|共8页
  • 作者单位

    From Pharmos Bioscience,Nordic Bioscience and Center for Clinical and Basic Research A/S, Herlev, Denmark;

    Ribe County Hospital,Esbjerg, Denmark;

    From Pharmos Bioscience,Nordic Bioscience and Center for Clinical and Basic Research A/S, Herlev, Denmark;

    and the Section of Medical Endocrinology,Research Institute, National University Hospital, Oslo, Norway;

    and the Department of Medicine,Research Institute, National University Hospital, Oslo, Norway;

    Hovedstadens Sygehusf?llesskab Blodbank,The University Hospital of Copenhagen, Copenhagen, Denmark;

    From Pharmos Bioscience,Nordic Bioscience and Center for Clinical and Basic Research A/S, Herlev, Denmark;

    and the Section of Medical Endocrinology,Research Institute, National University Hospital, Oslo, Norway;

    From Pharmos Bioscience,Nordic Bioscience and Center for Clinical and Basic Research A/S, Herlev, Denmark;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号